Key facts
- This page summarizes Edward Borkowski's Form 4 filing for TherapeuticsMD, Inc. (TXMD).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Jul 2021, 17:51.
Edward Borkowski - 01 Jul 2021 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)
- Reporting relationship
- EVP, Operations
- Issuer ticker
- TXMD
- Reported as of
- 01 Jul 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2021, 17:51:32 UTC
- Prior SEC filing
- 12 May 2021
- Next SEC filing
- 03 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edward Borkowski
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Edward Borkowski filed Form 4 for TherapeuticsMD, Inc. (TXMD) on 02 Jul 2021.
Change
- Previous filing in this sequence was filed on 12 May 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TXMD
transaction
Derivative
Performance Stock Units
Award
- Transaction value
- $0
- Shares
- +373,333
- Change %
- Price
- $0.000000
- Shares after
- 373,333
- Date
- 01 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 373,333
- Exercise price
- $0.000000
- Footnotes
- F1
TXMD
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +186,667
- Change %
- Price
- $0.000000
- Shares after
- 186,667
- Date
- 01 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 186,667
- Exercise price
- $0.000000
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.
Footnote F2
Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.